Related Experiment Video
Updated: Aug 6, 2026

Site-Specific Lysine Lactylation via Genetic Code Expansion in E. coli and Mammalian Cells
Published on: February 24, 2026
A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death
Meredith N Nix1, Sai Gourisankar2, Kevin J Bowman3
1Department of Chemical and Systems Biology, Stanford University, Stanford, CA, USA; Department of Chemistry, Stanford University, Stanford, CA, USA.
Abstract:
Developing cancer therapies that induce specific death of malignant cells is critical for preventing relapse. Highly effective strategies, such as immunotherapy, exemplify this principle. Here, we provide the mechanistic basis for a small-molecule approach that leverages chemically induced proximity (CIP) to kill diffuse large B cell lymphoma, the most common non-Hodgkin lymphoma. We developed lysine acetyltransferase (KAT)-based TCIPs (transcriptional/epigenetic chemical inducers of proximity), or KAT-TCIPs, which redirect p300/CREB-binding protein (CBP) to activate cell-death networks repressed by the oncogenic driver BCL6. Our lead KAT-TCIP reprograms the epigenome to initiate apoptosis. The crystal structure of the chemically induced p300-BCL6 complex reveals how chance protein-protein interactions may be exploited to confer the potency and selectivity of KAT-TCIPs. Thus, oncogenic drivers can be co-opted to activate robust cell death. Consistent with their gain-of-function mechanism, TCIPs recruiting different transcriptional activators-p300, BRD4, or CDK9-produce distinct genomic responses, suggesting specialized therapeutic uses.
Insights
Scientists developed novel small-molecule therapies called KAT-TCIPs to target diffuse large B cell lymphoma. These therapies reprogram the epigenome, activating cell death pathways and offering a new approach for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Chemical Biology
Background:
- Developing targeted cancer therapies that induce specific cancer cell death is crucial for preventing relapse.
- Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, necessitating effective treatment strategies.
Purpose of the Study:
- To provide the mechanistic basis for a small-molecule approach using chemically induced proximity (CIP) to kill DLBCL cells.
- To develop novel transcriptional/epigenetic chemical inducers of proximity (TCIPs) that leverage lysine acetyltransferase (KAT) activity.
Main Methods:
- Development of KAT-based TCIPs (KAT-TCIPs) designed to redirect p300/CREB-binding protein (CBP) activity.
- Utilizing the crystal structure of the chemically induced p300-BCL6 complex to understand potency and selectivity.
- Investigating the genomic responses of TCIPs recruiting different transcriptional activators (p300, BRD4, CDK9).
Main Results:
- The lead KAT-TCIP reprograms the epigenome to initiate apoptosis in DLBCL cells.
- The study revealed how protein-protein interactions can be exploited for therapeutic effect.
- Distinct genomic responses were observed based on the recruited transcriptional activator, suggesting specialized therapeutic applications.
Conclusions:
- Oncogenic drivers can be co-opted to activate robust cell death pathways.
- KAT-TCIPs represent a promising small-molecule strategy for targeting DLBCL by inducing specific cancer cell death.
- The mechanism provides a foundation for developing tailored TCIP-based therapies for various cancers.
Related Concept Videos
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
The Intrinsic Apoptotic Pathway
Anaphase Promoting Complex
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Extrinsic Apoptotic Pathway
Intracellular Signaling Affects Focal Adhesions
Some...

